查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836767

神經病變疼痛治療​​市場（按產品類型、給藥途徑、適應症和分銷管道）—全球預測 2025-2032

Neuropathic Pain Drug Market by Product Type, Route Of Administration, Indication, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年神經病變疼痛藥物市場將成長至 284.7 億美元，複合年成長率為 10.39%。

主要市場統計數據
基準年2024年 129億美元
預計2025年 142.2億美元
預測年份：2032年 284.7億美元
複合年成長率（%） 10.39%

對多方面神經病變疼痛治療​​領域的權威定位，強調臨床複雜性、付款人壓力和不斷發展的治療選擇

神經病變疼痛帶來了持續且複雜的臨床挑戰，需要不斷改善治療模式、加強監管參與並提高商業性靈活性。糖尿病性神經病變、化療引起的神經病變、HIV相關神經病變以及帶狀皰疹後遺症神經痛患者常常會出現對傳統疼痛治療方法無效的慢性症狀，這促使臨床醫生和研究人員尋求多學科策略。近年來，臨床界已看到關於既定藥理學類別藥物的證據趨於一致，同時神經調節裝置和局部製劑也在不斷創新，從而拓展了治療選擇。因此，如今的處方行為反映了療效數據、耐受性概況和監管建議之間的平衡。

同時，由於鴉片類藥物安全隱患以及對加巴噴丁類藥物濫用的審查力度加大，付款人和採購團隊正在加強准入控制，這兩者都影響了處方集的分配和事先核准要求。這種環境凸顯了差異化價值提案和清晰的現實世界證據的重要性，這些證據能夠證明藥物的功能和生活品質改善。此外，隨著製造商重新評估地域依賴性，供應鏈彈性和原料藥採購已成為商業化計畫中的策略考量。標靶治療的引入、局部用藥配方的改進以及對基於指南的治療的重視，正在共同改變相關人員對神經病變疼痛領域臨床項目和商業投資的優先排序方式。

科學突破、監管執行和商業性重組的策略整合正在重新定義治療方法發展和應用的軌跡

在神經病變疼痛領域，科學、安全和系統層面的壓力正在推動治療方法開發、應用和報銷方面的重大變革，包括小分子離子通道調節劑、亞型選擇性鈉通道策略以及調節周邊和中樞敏化的生物學方法。這條科學軸線與製劑創新相輔相成，例如高濃度局部貼片和改進的經皮給藥系統，這些系統在提高局部療效的同時限制了全身暴露，從而解決了耐受性和監管問題。

同時，臨床實踐正受到監管審查力度加大和長期安全性證據標準不斷演變的影響，這不僅限制了日常鴉片類藥物依賴，也促使人們更加密切地關注加巴噴丁類藥物的不利事件特徵。這些趨勢正加速人們對整合藥理學、設備輔助和復健方法的多模態治療途徑的興趣。在商業性，相關人員面臨著證明對付款人重要的療效的壓力，例如降低醫療保健利用率和改善患者報告療效，從而推動了對真實世界證據生成和自適應定價模型的投資。總而言之，這些轉變正在重塑價值鏈，並為那些將科學差異化與實際交付和證據生成計劃相結合的公司創造戰略窗口。

批判性地評估最近的關稅行動如何重塑治療價值鏈中相關人員的供應鏈策略、採購慣例和成本控制

美國近期的關稅措施神經病變中的供應商、製造商和經銷商帶來了新的商業考量。某些進口原料和成品成本的上漲，迫使採購團隊重新評估其供應商組合，並考慮採用近岸外包或雙重採購策略，以穩定利潤率並確保供應的連續性。依賴離岸原料藥)生產的公司必須模擬多個製造環節的累積成本影響，並將關稅相關的波動性納入合約談判和庫存政策中。

這些發展也影響著定價策略的討論，製造商正在評估是否可以透過產品重新定位、配方最佳化或專注於國內製造能力來減輕關稅的影響。付款人和承包組織對下游成本變化表現出敏感性，這導致對更嚴格的配方控制和經濟合理性的需求日益增加。為此，一些公司正在加快與位於優惠關稅管轄區的製造外包建立合作夥伴關係，並加強供應商資格認證計劃，以減少對單一來源的依賴。因此，供應鏈視覺性、情境規劃和主動的政策參與已成為組織尋求在不影響患者取得藥品的情況下保持競爭力的關鍵能力。

細緻的細分解釋揭示了治療層級、給藥途徑、臨床適應症和分銷管道如何決定臨床定位和商業性策略

細分分析揭示了治療層級、給藥途徑、臨床指徵和通路之間的差異化動態，這為產品定位和開發重點提供了資訊。按產品類型分類，抗驚厥藥、抗憂鬱症、鴉片類藥物和外用藥物等既定類別繼續支撐治療流程，但它們的內部組成和臨床作用差異很大。透過探索Carbamazepine、加巴噴丁、拉莫三嗪和Gabapentin等藥物，抗驚厥藥物持續在控制各種病因的神經病變症狀方面發揮核心作用。同時，以 SNRI 和Pregabalin（如Duloxetine、文拉法辛、阿米替林和去甲替林）為代表的抗憂鬱症是同時出現憂鬱症狀或中樞敏化時的重要選擇。

在效益風險評估和法規允許的範圍內，Tapentadol和曲馬多等鴉片類藥物發揮關鍵作用，但其使用仍然有限，且需在嚴密監測的治療窗口內。辣椒素、雙氯芬酸鈉凝膠和Lidocaine貼片等外用製劑對有多重用藥風險的人具有吸引力，因為它們可以局部緩解症狀，且全身性安全隱患較少。考慮給藥途徑——靜脈注射、口服、局部或經皮——會在依從性、起效時間和耐受性方面做出權衡，進而影響臨床偏好和報銷決策。化療引起的神經病變、糖尿病性神經病變、HIV 相關神經病變和帶狀皰疹後遺症神經痛等適應症的具體細微差別進一步影響臨床試驗設計和證據要求。最後，從醫院藥房到零售藥房和專科診所的分銷管道決定了獲取模式、患者教育機會以及公司必須協調以實現有效商業化的管道特定合約策略。

深入的區域評估，結合監管概況、付款人期望和供應鏈現實情況，為特定區域的市場進入和擴大策略提供資訊

區域動態對監管趨勢、臨床實踐模式和供應鏈設計有著強大的影響，因此需要在關鍵區域制定客製化策略。在美洲，醫療保健系統的特點是高度重視支付方主導的證據、比較有效性和管理式醫療處方集流程。這些壓力獎勵商產生真實世界結果數據並儘早與支付方溝通。監管預期和訴訟環境也會影響風險管理策略和處方指南，尤其是在鴉片類藥物管理計劃和濫用威懾方面。在歐洲、中東和非洲，分散的報銷體系和多樣化的監管途徑為特定區域的價值驗證帶來了複雜性和機會。自適應定價模型和特定區域的臨床證據包通常決定了市場進入的時間表。

在亞太地區，新藥配方的快速推出和高容量治療環境與不同程度的監管成熟度和不斷成長的國內生產能力並存，影響許可策略和夥伴關係模式。供應鏈考量也因地區而異，韌性措施、關稅影響和物流限制導致每個地區採用不同的採購方式。因此，成功的區域策略需要結合監管知識、符合當地臨床標準的證據產生以及考慮區域製造地和分銷基礎設施的供應鏈設計，以保持醫療保健的連續性並最佳化商業性回報。

對產業參與者的角色、夥伴關係模式和能力差距進行策略評估，這將決定誰能在差異化、創新主導的治療產業格局中勝出

神經病變疼痛領域的企業動態體現了傳統製藥公司、學名藥製造商、專業生物技術公司和合約服務供應商的多元化格局，它們各自在為患者提供治療方案方面發揮著互補作用。老牌製藥公司擁有豐富的臨床試驗經驗和監管記錄，支持生命週期管理和產品說明書擴展工作；而學名藥製造商則提供關鍵的可及性藥物，為標準治療方案奠定基礎。新興生物技術和專業開發公司正在推動差異化機制和標靶給藥技術，以滿足尚未滿足的需求，通常透過有針對性的臨床計畫和與大型合作夥伴的策略聯盟來實現。

受託製造廠商、製劑專家和數位療法供應商正成為商業化策略的關鍵，他們提供能夠實現快速規模化、替代交付方式和依從性技術的能力。在整個生態系統中，夥伴關係、授權協議和選擇性併購活動正在加速早期資產轉化為具有臨床意義的選項的轉變。競爭成功越來越依賴一種綜合方法，該方法將科學差異化與強大的證據生成計劃、靈活的生產佈局以及專注於以患者為中心的結果和總護理成本的付款人參與策略相結合。

一份實用的劇本，概述了優先的策略舉措和營運保障措施，以使科學差異化與以付款人為中心的證據和彈性供應鏈設計保持一致

尋求抓住神經性疼痛領域機會的領導者必須採取一系列協調一致的行動，將科學差異化與商業性執行結合在一起。首先，投資於機制驅動的臨床項目和真實世界證據，這些項目和證據與付款方的優先事項和患者重視的功能終點直接相關。其次，優先考慮原料藥供應商的彈性，並透過多元化原料藥來源、確定區域契約製造製造商以及將關稅情境規劃納入採購協定來降低貿易政策變化帶來的風險。第三，設計強調耐受性、功能結果和總護理成本的價值提案，並在可行的情況下結合自適應定價和基於結果的合約。

其他優點包括與專科診所和醫院系統建立策略夥伴關係，打造卓越中心，檢驗臨床效益並產生早期真實世界數據。利用配方創新，提供差異化的給藥方案，尤其是局部和經皮方案，以降低系統性風險。最後，儘早協調監管、臨床開發和商業團隊，以簡化標籤策略、上市後核准承諾和付款人參與藍圖，從而支持在多元化醫療環境中快速持續地推廣。

我們透過結合專家初步訪談、嚴格的二次檢驗和情境分析的透明且可複製的研究框架來支持策略決策。

本文件所依據的研究採用了混合方法，將專家的初步研究與嚴格的二次綜合和檢驗相結合。主要輸入包括對臨床醫生、監管專家、供應鏈高管和付款人的結構化訪談，以了解他們對臨床實踐、獲取障礙和採購動態的現場觀點。這些定性輸入與監管出版物、臨床試驗註冊中心、同行評審文獻和製造商披露資訊進行交叉引用，以構建將治療機制與臨床結果和安全性聯繫起來的證據圖譜。

分析方法包括比較機制分析、給藥途徑影響評估、特定適應症證據綜合以及供應商風險評分，以評估供應鏈的脆弱性。基於情境的敏感度測試檢驗了關稅制度和替代籌資策略對營運的影響，而無需依賴專有的商業性估算。品管措施包括研究結果的交叉檢驗、專家的獨立同行評審以及資料來源和假設的透明記錄，以支持可重複性並使相關人員能夠適應客製化的調查方法。

簡潔的策略綜合強調了協調臨床創新、付款人證據和營運彈性以產生持續的商業性和患者影響的必要性

總而言之，神經病變疼痛治療​​領域正處於曲折點，科學創新、監管格局、付款方期望和供應鏈現狀既帶來了風險，也帶來了機會。差異化機制和創新劑型為解決患者未滿足需求並緩解系統性安全隱患提供了途徑，但成功取決於臨床證據產生、付款方參與和彈性營運設計之間的協調一致。能夠將有針對性的臨床項目與可靠的現實世界結果、多元化的製造地和靈活商業模式相結合的組織，將最有能力創造永續的價值。

展望未來，相關人員應預期將繼續重視基於結果的評估，加強對系統性藥物安全性的審查，並在適當的情況下更傾向於局部交付解決方案。對本地證據生成、區域製造夥伴關係關係以及以付款人為中心的價值敘事的策略性投資，將使公司能夠應對政策變化和可及性限制，同時改善患者照護。商業性和臨床影響的路徑將取決於能否將機制承諾轉化為跨不同醫療環境的可衡量效益。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將精準醫療與基因分析整合到神經病變疼痛治療​​方案中
  • 針對 Nav1.7 的新興鈉通道阻斷劑用於治療帶狀皰疹後遺症神經痛
  • 以大麻素和加巴噴丁類藥物聯合治療通訊協定治療周邊神經神經病變
  • 擴展數位健康監測工具，用於即時評估神經病變疼痛症狀
  • 促進糖尿病神經病變罕見神經病變疼痛適應症發展的監管獎勵
  • 率先使用基因治療方法調節神經病變患者的疼痛訊號通路
  • 真實世界證據研究對新型神經病變疼痛治療​​處方決策的影響
  • 臨床試驗中越來越關注以病人為中心的結果測量和生活品質終點

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章神經病變疼痛治療​​市場（依產品類型）

  • 抗驚厥藥
    • Carbamazepine
    • Gabapentin
    • 拉莫三嗪
    • Pregabalin
  • 抗憂鬱症
    • SNRI
      • Duloxetine
      • 文拉法辛
    • TCA
      • 阿米替林
      • 去甲替林
  • 鴉片類藥物
    • Tapentadol
    • 曲馬多
  • 局部藥物
    • 辣椒素
    • 雙氯芬酸鈉凝膠
    • Lidocaine貼劑

第9章神經病變疼痛治療​​市場（依給藥途徑）

  • 靜脈
  • 口服
  • 外用
  • 經皮

第 10 章神經病變疼痛治療​​市場（按適應症）

  • 化療引起的神經病變
  • 糖尿病神經神經病變
  • HIV相關神經病變
  • 帶狀皰疹後遺症神經痛

第 11 章神經病變疼痛治療​​市場（依通路）

  • 醫院藥房
  • 零售藥局
  • 專科診所

第12章神經病變疼痛治療​​市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章神經病變疼痛治療​​市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章神經病變疼痛治療​​市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Mylan NV
    • Novartis AG
    • Eli Lilly and Company
    • Grunenthal GmbH
    • Endo International plc
    • Bausch Health Companies Inc.
    • Hikma Pharmaceuticals PLC
    • AcelRx Therapeutics, Inc.
Product Code: MRR-036C5CF3B4DE

The Neuropathic Pain Drug Market is projected to grow by USD 28.47 billion at a CAGR of 10.39% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.90 billion
Estimated Year [2025] USD 14.22 billion
Forecast Year [2032] USD 28.47 billion
CAGR (%) 10.39%

An authoritative orientation to the multifaceted neuropathic pain treatment environment stressing clinical complexity, payer pressure, and evolving therapeutic choices

Neuropathic pain presents a persistent and complex clinical challenge that demands evolving therapeutic paradigms, regulatory engagement, and commercial agility. Patients affected by diabetic neuropathy, chemotherapy-induced neuropathy, HIV-associated neuropathy, and post-herpetic neuralgia frequently experience chronic symptoms that resist conventional analgesic approaches, prompting clinicians and researchers to seek multimodal strategies. Over recent years, the clinical community has consolidated evidence for agents across established pharmacologic classes, and parallel innovations in device-based neuromodulation and topical formulations have broadened treatment options. As a result, prescribing behavior reflects a balance between efficacy data, tolerability profiles, and regulatory advisories.

Concurrently, payers and procurement teams have tightened access controls, driven by safety concerns around opioids and heightened scrutiny of gabapentinoid misuse, which together influence formulary placements and prior authorization requirements. This environment elevates the importance of differentiated value propositions and clear real-world evidence demonstrating functional and quality-of-life outcomes. Moreover, supply chain resilience and API sourcing have become strategic considerations for commercialization planning, as manufacturers re-evaluate geographic dependencies. The introduction of targeted therapies, improved formulations for topical administration, and stronger emphasis on guideline-concordant care are collectively reshaping how stakeholders prioritize clinical programs and commercial investments in the neuropathic pain domain.

A strategic synthesis of scientific breakthroughs, regulatory tightening, and commercial realignment that is redefining therapeutic development and adoption pathways

The neuropathic pain landscape is undergoing transformative shifts driven by science, safety, and system-level pressures that change how therapies are developed, adopted, and reimbursed. Mechanistic advances are steering innovation toward modalities that go beyond symptomatic relief to target pathophysiology, including small molecule ion channel modulators, subtype-selective sodium channel strategies, and biologic approaches that aim to modulate peripheral and central sensitization. This scientific pivot is complemented by formulation innovations such as high-concentration topical patches and improved transdermal delivery systems that enhance localized efficacy while limiting systemic exposure, thereby addressing tolerability and regulatory concerns.

At the same time, clinical practice is influenced by heightened regulatory scrutiny and evolving evidence standards for long-term safety, which have curtailed routine opioid reliance and prompted deeper examination of gabapentinoid adverse event profiles. These dynamics have accelerated interest in multimodal care pathways that integrate pharmacologic, device-based, and rehabilitative approaches. Commercially, stakeholders face pressure to demonstrate outcomes that matter to payers, including reduced healthcare utilization and improved patient-reported outcomes, which in turn drives investment in real-world evidence generation and adaptive pricing models. Collectively, these shifts are reconfiguring value chains and creating strategic windows for companies that align scientific differentiation with pragmatic delivery and evidence-generation plans.

A rigorous assessment of how recent tariff measures have reshaped supply chain strategies, procurement practices, and cost management for stakeholders in the therapeutic value chain

Recent tariff initiatives in the United States have introduced a new operational calculus for suppliers, manufacturers, and distributors within the neuropathic pain drug ecosystem. Elevated costs on specific imported raw materials and finished goods have pressured procurement teams to reassess supplier portfolios and to examine nearshoring or dual-sourcing strategies in order to stabilize margins and secure continuity of supply. Firms reliant on offshore API production have had to model the cumulative cost implications across multiple manufacturing tiers and to incorporate tariff-related variability into contractual negotiations and inventory policies.

These developments have also influenced pricing strategy discussions, with manufacturers evaluating whether product repositioning, formulation optimization, or greater emphasis on domestic manufacturing capacity can mitigate tariff exposure. Payers and contracting organizations have signaled sensitivity to downstream cost shifts, leading to more stringent formulary management and heightened demand for economic evidence. In response, several organizations have accelerated engagement with contract manufacturing organizations located within tariff-favorable jurisdictions and have intensified supplier qualification programs to reduce single-source dependencies. As a result, supply chain visibility, scenario planning, and proactive policy engagement have become critical capabilities for organizations aiming to maintain competitive positioning while ensuring uninterrupted patient access.

A nuanced segmentation narrative revealing how therapeutic classes, administration routes, clinical indications, and distribution channels determine clinical positioning and commercial tactics

Segmentation analysis reveals differentiated dynamics across therapeutic classes, routes of administration, clinical indications, and distribution pathways that collectively inform product positioning and development priorities. Within product type, established classes such as anticonvulsants, antidepressants, opioids, and topical agents continue to anchor treatment algorithms, but their internal composition and clinical roles differ significantly. Anticonvulsants, examined through agents such as carbamazepine, gabapentin, lamotrigine, and pregabalin, continue to be central to neuropathic symptom control in diverse etiologies, while antidepressants are represented by SNRIs and TCAs, including duloxetine, venlafaxine, amitriptyline, and nortriptyline, which serve as key alternatives where comorbid depressive symptoms or central sensitization are prominent.

Opioids, including tapentadol and tramadol, retain a focused role where benefit-risk assessments and regulatory controls permit, but their use exists within a constrained and closely monitored therapeutic window. Topical agents, with options such as capsaicin, diclofenac gel, and lidocaine patch, offer meaningful localized relief and present lower systemic safety concerns, thereby appealing to populations with polypharmacy risks. Route of administration considerations-spanning intravenous, oral, topical, and transdermal options-drive adherence, onset of action, and tolerability trade-offs, which in turn shape clinical preference and reimbursement decisions. Indication-specific nuances for chemotherapy-induced neuropathy, diabetic neuropathy, HIV-associated neuropathy, and post-herpetic neuralgia further influence clinical trial design and evidence requirements. Finally, distribution channels ranging from hospital pharmacies to retail pharmacies and specialty clinics determine access patterns, patient education opportunities, and channel-specific contracting strategies that companies must tailor to for effective commercialization.

An incisive regional assessment that connects regulatory traits, payer expectations, and supply chain realities to inform geographically specific market entry and expansion strategies

Regional dynamics exert powerful influence on regulatory trajectories, clinical practice patterns, and supply chain design, requiring tailored strategies across major geographies. In the Americas, health systems are characterized by a strong emphasis on payer-driven evidence, comparative effectiveness, and managed care formulary processes; these pressures incentivize manufacturers to generate real-world outcomes data and to engage early with payers. Regulatory expectations and litigation environments also shape risk management strategies and prescribing guidelines, particularly where opioid stewardship programs and abuse-deterrence concerns are salient. Moving to Europe, Middle East & Africa, fragmented reimbursement regimes and varied regulatory pathways create both complexity and opportunity for localized value demonstration; adaptive pricing models and region-specific clinical evidence packages often determine market access timelines.

In the Asia-Pacific region, rapid adoption of new formulations and high-volume treatment settings coexist with diverse regulatory maturity and growing domestic manufacturing capacity, which influences licensing strategies and partnership models. Supply chain considerations differ by region as well; resiliency initiatives, tariff exposure, and logistics constraints prompt distinct sourcing approaches across these geographies. Successful regional strategies therefore combine regulatory savvy, evidence generation aligned with local clinical standards, and supply chain designs that consider regional manufacturing hubs and distribution infrastructures to maintain continuity of care and optimize commercial return.

A strategic appraisal of industry participant roles, partnership models, and capability gaps that determine who wins in a differentiated and innovation-driven therapeutic landscape

Company dynamics in the neuropathic pain arena reflect a mosaic of legacy pharmaceutical firms, generics manufacturers, specialty biotechs, and contract service providers, each playing complementary roles in bringing therapies to patients. Established pharmaceutical companies maintain deep clinical trial experience and regulatory track records that support lifecycle management and label expansion efforts, while generic manufacturers supply critical access medicines that define baseline standard-of-care choices. Emerging biotechs and specialty developers are advancing differentiated mechanisms and targeted delivery technologies that aim to address unmet needs, often through focused clinical programs and strategic collaborations with larger partners.

Contract manufacturing organizations, formulation specialists, and digital therapeutics vendors have become integral to commercialization strategies, offering capabilities that enable rapid scale-up, alternative delivery formats, and supportive adherence technologies. Across the ecosystem, partnerships, licensing arrangements, and selective M&A activity have accelerated the translation of early-stage assets into clinically meaningful options. Competitive success increasingly depends on an integrated approach that aligns scientific differentiation with robust evidence-generation plans, flexible manufacturing footprints, and payer engagement strategies that emphasize patient-centered outcomes and total cost of care implications.

A pragmatic playbook of prioritized strategic moves and operational safeguards that align scientific differentiation with payer-centered evidence and resilient supply chain design

Leaders seeking to capture opportunity in the neuropathic pain domain must pursue a set of coordinated actions that bridge scientific differentiation and commercial execution. First, invest in mechanism-linked clinical programs and real-world evidence generation that directly speak to payer priorities and functional endpoints valued by patients; this will accelerate formulary acceptance and clinician uptake. Second, prioritize supply chain resilience by diversifying API sources, qualifying regional contract manufacturers, and embedding tariff scenario planning into procurement contracts to reduce exposure to trade policy shifts. Third, design value propositions that emphasize tolerability, functional outcomes, and total cost of care, and couple these with adaptive pricing and outcomes-based contracting where feasible.

Additionally, cultivate strategic partnerships with specialty clinics and hospital systems to create centers of excellence that can both validate clinical benefits and generate early real-world data. Leverage formulation innovation to offer differentiated delivery profiles, particularly topical and transdermal solutions that reduce systemic risk. Finally, align regulatory affairs, clinical development, and commercial teams early to streamline label strategy, post-approval evidence commitments, and payer engagement roadmaps that support rapid, durable uptake across heterogeneous healthcare settings.

A transparent and reproducible research framework combining expert primary interviews, rigorous secondary validation, and scenario analysis to underpin strategic decision-making

The research underpinning this dossier employed a mixed-methods approach that integrates expert primary research with rigorous secondary synthesis and validation. Primary inputs included structured interviews with clinicians, regulatory specialists, supply chain executives, and payers to capture frontline perspectives on clinical practice, access barriers, and procurement dynamics. These qualitative inputs were triangulated with regulatory announcements, clinical trial registries, peer-reviewed literature, and manufacturer disclosures to construct an evidence map linking therapeutic mechanisms to clinical outcomes and safety profiles.

Analytical methods included comparative mechanism analysis, route-of-administration impact assessment, indication-specific evidence synthesis, and supplier risk scoring to evaluate supply chain vulnerabilities. Scenario-based sensitivity testing examined the operational impact of tariff regimes and alternative sourcing strategies without relying on proprietary commercial estimates. Quality control measures included cross-validation of interview findings, independent peer review by subject matter experts, and transparent documentation of data sources and assumptions to support reproducibility and to enable stakeholders to adapt the methodology for bespoke inquiries.

A concise strategic synthesis that underscores the imperative to align clinical innovation, payer evidence, and operational resilience to realize durable commercial and patient impact

In conclusion, the neuropathic pain treatment landscape is at an inflection point where scientific innovation, regulatory dynamics, payer expectations, and supply chain realities converge to create both risk and opportunity. Differentiated mechanisms and novel formulations provide pathways to address unmet patient needs while reducing systemic safety concerns, but success depends on coherent alignment between clinical evidence generation, payer engagement, and resilient operational design. Organizations that integrate targeted clinical programs with robust real-world outcomes, diversified manufacturing footprints, and adaptive commercial models will be best positioned to deliver sustainable value.

Going forward, stakeholders should anticipate continued emphasis on outcome-based evaluation, tighter scrutiny of safety profiles for systemically acting agents, and increased preference for localized delivery solutions where appropriate. Strategic investment in localized evidence generation, regional manufacturing partnerships, and payer-centered value narratives will enable companies to navigate policy shifts and access constraints while improving patient care. The path to commercial and clinical impact will be defined by the ability to translate mechanistic promise into measurable benefits across diverse healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of precision medicine and genetic profiling in neuropathic pain treatment options
  • 5.2. Emergence of novel sodium channel blockers targeting Nav1.7 for postherpetic neuralgia management
  • 5.3. Adoption of combination therapy protocols incorporating cannabinoids and gabapentinoids in peripheral neuropathy
  • 5.4. Expansion of digital health monitoring tools for real-time assessment of neuropathic pain symptoms
  • 5.5. Regulatory incentives driving development of orphan neuropathic pain indications in diabetic neuropathy
  • 5.6. Pioneering use of gene therapy approaches to modulate pain signaling pathways in neuropathic patients
  • 5.7. Impact of real-world evidence studies on formulary decisions for emerging neuropathic pain treatments
  • 5.8. Growing focus on patient-centric outcome measures and quality-of-life endpoints in clinical trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuropathic Pain Drug Market, by Product Type

  • 8.1. Anticonvulsants
    • 8.1.1. Carbamazepine
    • 8.1.2. Gabapentin
    • 8.1.3. Lamotrigine
    • 8.1.4. Pregabalin
  • 8.2. Antidepressants
    • 8.2.1. SNRIs
      • 8.2.1.1. Duloxetine
      • 8.2.1.2. Venlafaxine
    • 8.2.2. TCAs
      • 8.2.2.1. Amitriptyline
      • 8.2.2.2. Nortriptyline
  • 8.3. Opioids
    • 8.3.1. Tapentadol
    • 8.3.2. Tramadol
  • 8.4. Topical Agents
    • 8.4.1. Capsaicin
    • 8.4.2. Diclofenac Gel
    • 8.4.3. Lidocaine Patch

9. Neuropathic Pain Drug Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Topical
  • 9.4. Transdermal

10. Neuropathic Pain Drug Market, by Indication

  • 10.1. Chemotherapy-Induced Neuropathy
  • 10.2. Diabetic Neuropathy
  • 10.3. HIV-Associated Neuropathy
  • 10.4. Post-Herpetic Neuralgia

11. Neuropathic Pain Drug Market, by Distribution Channel

  • 11.1. Hospitals Pharmacy
  • 11.2. Retail Pharmacies
  • 11.3. Specialty Clinics

12. Neuropathic Pain Drug Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neuropathic Pain Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neuropathic Pain Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Pfizer Inc.
    • 15.3.2. Teva Pharmaceutical Industries Ltd.
    • 15.3.3. Mylan N.V.
    • 15.3.4. Novartis AG
    • 15.3.5. Eli Lilly and Company
    • 15.3.6. Grunenthal GmbH
    • 15.3.7. Endo International plc
    • 15.3.8. Bausch Health Companies Inc.
    • 15.3.9. Hikma Pharmaceuticals PLC
    • 15.3.10. AcelRx Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROPATHIC PAIN DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-